Targeting HSP70 in tumor and mitochondrial compartments drives immunogenic cell death, boosts immune infiltration, and limits tumor growth.
Linear ALK inhibitors extend treatment to ALK-negative, LTK-positive myeloma by triggering ER stress and apoptosis in hypersecretory cells.
Small molecules bridge BTN3A1 and BTN2A1 to activate Vγ9Vδ2 T cells while improving plasma stability and drugability.